This is the authors' abstract. We don't add key points for this paper.
Intraductal papillary mucinous neoplasms (IPMNs) account for the majority of incidentally found pancreatic cystic neoplasms. There are three general subtypes: main-duct (MD-IPMN), branch-duct (BD-IPMN), and mixed-type (MT-IPMN) which all carry varying degrees of malignant potential. The malignant risk of IPMN involving the main pancreatic duct ranges from 40 to 80% for both MD-IPMN and MT-IPMN, while the malignancy risk for BD-IPMN is more variable but considered to be much lower. The management of BD-IPMN is typically non-operative surveillance and remains a topic of debate. In this overview, we discuss the current controversies in management of BD-IPMN such as comparison of surveillance strategies based on consensus guidelines, perceived weight of various worrisome features (WF) and/or high-risk stigmata (HRS), molecular analyses, multifocality, cost effectiveness strategies, and high patient-risk features. This overview should provide a glimpse into the current state and controversies in the care of patients with BD-IPMN.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Mayhew et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: